TNBC is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2, rendering it unresponsive to hormone therapies or HER2‐targeted treatments commonly used for other breast cancer subtypes (Bianchini et al. 2022). This evidence concerns the gene ERBB2 and breast cancer.